Inc. is a holding company that owns all of the capital stock of Xechem,
Inc., a development stage biopharmaceutical company engaged in the
and technology development of generic and drugs from natural sources.
and development efforts focus principally on antifungal, anticancer,
(including anti-AIDS) and anti-inflammatory compounds, as well as
and memory enhancing compounds. Xechem is also focusing on
and other technologies for orphan diseases. As of December 31, 2006,
Company's lead project involved the development of a
product, NICOSAN/HEMOXIN). The development and production of
is being conducted through Xechem Nigeria, Xechem Research Laboratories
of Xechem, Inc. and Children’s Hospital of Philadelphia. In November
the Company, along with Xechem, filed voluntary petitions for relief
Chapter 11 of the United States Bankruptcy Code.
States - Map